Understanding the causes and outcomes of lymphoma in Chinese patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe the clinical and genetic characteristics of lymphoma patients in China, focusing on both Hodgkin and Non-Hodgkin lymphoma. By collecting real-world data from clinical practice, the study will explore the relationship between these characteristics and the pathogenesis and prognostic factors of lymphoma. The data gathered will include patient demographics, tumor characteristics, treatment history, and outcomes, providing insights into the disease's behavior in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
* Patients with complete diagnostic, treatment and follow-up records.
* Fully comprehension and signature of the informed consent form (ICF) for participation.

Exclusion Criteria:

* Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
* Severe mental illness.
* Patients deemed unsuitable for inclusion by the investigator.

Where it's running

• Zhongshan Hospital，Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Peng Liu, Ph.D
• Email: liu.peng@zs-hospital.sh.cn
• Phone: +862164041990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Carmustine treatment for lymphoma patients

  This study is testing if adding a new drug called VI-0609 to a standard treatment helps lymphoma patients do better after a stem cell transplant.

  Recruiting at 4 sites Phase 2 Vivus LLC · Goodyear, Arizona and 3 other locations · NCT06915246

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Evaluating AZD3470 for relapsed or refractory blood cancers

  This study is testing a new drug called AZD3470 to see if it can help people with hard-to-treat blood cancers feel better and respond to treatment.

  Recruiting at 28 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT06137144

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.